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Mini-Review
Abstract
Background and aims: Vitiligo is an acquired, idiopathic, and common depigmentation disorder of the 
skin that affects people of all ages and both sexes equally worldwide. Although etiology of the disease 
is unknown, there are theories such as environment and genetic factors.
Methods: In this article, we collected and summarized the appropriate manuscripts regarding the 
epidemiology and genetics using the terms vitiligo and genetic epidemiology in PubMed and Google 
Scholar. 
Results: Studies showed the highest prevalence of disease in African countries, but with regard to the 
distribution of disease in different areas, environmental factors were as important as other causes of 
vitiligo, and 3 genes of FOXP3, XBP1 and TSLP had the most association with the disease.
Conclusion: It seems that recognition of the genetic basis of vitiligo will supply new insight into the 
therapies for it. Therefore, more genetic studies are needed to discover the genes and causes linked to 
clinical aspects of this disease. 
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Introduction
Vitiligo is an acquired cutaneous hypopigmentation 
disorder which affects 1%-4% of  the world’s population.1 
The clinical symptoms of  vitiligo are pale or milk-white 
macules or patches on different parts of  the body skin 
due to the selective destruction of  melanocytes.2 The 
clinical presentation of  vitiligo includes focal, vulgaris, 
segmental, universal, mucosal and mixed vitiligo.1 The 
cause of  the vitiligo is unknown but the interaction 
of  genetic and environmental factors is associated 
with the disease,3 as there is a positive family history 
in 30% of  the cases.4 There are also other major 
hypotheses for the pathogenesis of  vitiligo such as 
stress, accumulation of  toxic compounds, High H2O2 
level, infection, autoimmunity, mutations, altered cellular 
environment, and impaired melanocyte migration and 
proliferation.5 The most accepted theory is that vitiligo 
is an autoimmune disease, as the increased expression of 
pre-inflammatory and pre-apoptosis cytokines such as 
IL-6, IL-8, IL-10, IL-12, IFN-γ, TNF-α is associated with 
vitiligo pathogenesis and cause the death of  these cells 
by changing the pigment of  melanocytes.6,7 Moreover, 
immunohistochemical studies in the skin around the 
lesion suggests that stimulation of  the cytotoxic T-cell 
CD + 8 detecting MHCI-binding peptides derived from 
melanocyte proteins may play an important role in the 
pathophysiology of  vitiligo.8 
Medical therapy has been an exclusive treatment option 
for vitiligo during several decades, as re-pigmentation 
using UV light therapy and corticosteroid creams,9 
removing pigment from non-affected skin,10 grafting,11 
using an active form of  vitamin D (calcitriol) or 1, 
and 25 dihydroxyvitamin D3, and the analogue of  this 
hormone (such as calcium poutriol)12 have been used to 
improve the skin appearance of  affected people. In the 
recent decades, scientists have focused on non-medical 
treatment options as a first-line or an adjuvant therapy. 
For instance, Siadat et al compared NB-UVB with oral 
minocycline in unstable vitiligo treatment and their 
results showed that NB-UVB was more advantageous 
than oral minocycline in terms of  efficacy and the 
resulting stability.13
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The latest non-medical option in the treatment of 
vitiligo and management of  melanocyte distribution is 
surgical intervention.14-16 Hair follicular transplant is one 
of  these various surgical modalities that are followed to 
re-pigment the vitiligo patches. In this case, Aziz Jalali et 
al used hair follicle autograft transplant in the persistent 
segmental vitiligo treatment. Their results suggested this 
method as an effective treatment option.17
Epidemiology
Vitiligo has been known for at least 3500 years because 
of  its striking appearance18 as was first noted in the 
Old Testament, the Quran and Buddhist literature in 
approximately 1400 BC. 
It tends to occur or recur in spring and/or summer2,19 
and disease severity is inversely proportional to distance 
from the equator.20 It occurs mostly in dark-skinned 
individuals and its distribution differs in various 
geographical areas depending on skin types, ethnic 
groups, environmental conditions, genetic factors, 
ethnical and cultural diversity.21 Vitiligo is more frequent 
in females and 50% of  cases appear before 20 years of 
age and shows an inverse trend with age increment.21,22 
The reports on vitiligo epidemiology are based on 
population surveys and patients referred to dermatology 
clinics.19 
In population-based studies, the lowest prevalence was 
related to Asia and Atlantic (0.1%), the second rank was 
related to Africa and Europe (0.4%), and the highest 
frequency was seen in Oceania (1.2%). According to 
hospital-based studies, the lowest prevalence was related 
to America (1.5%) and Asia (1.6%) and the highest was 
in Africa (2.5%).21
Publications were arranged based on the year, from 
1997 to 2015. Some covered areas included India 
(9.98%), China (0.15%), Saudi Arabia (0.32%), Sri Lanka 
(1.22%), Turkey (1.44%), Nepal (0.91%), Iran (1.82%), 
Korea (0.13%), Japan(1.68%) in Asia, Tanzania (0.71%), 
Egypt (0.06%), Nigeria (2.8%) in Africa, Brazil (0.04%), 
the United States (2.42%), Mexico (2.6%) in America, 
Denmark (0.38%), Italy (0.17%), Germany (0.57%), 
France (0.28%) in Europe, and Australia (1.2%).21
In Asia, except for Saudi Arabia (18-45 years old), in 
Europe except for Italy (only 18 years old) and Germany 
(14-86 years old) and in America except for USA (1-
60 years old), all age groups were equally affected. In 
Australia the prevalence of  vitiligo was found among 
adults (15-21 years old.21
Genetic Epidemiology
Despite a long history of  this dermatosis, the exact 
pathogenesis of  vitiligo is still unknown. Although 
environmental factors are important, several genetic 
epidemiological studies on twins and families have also 
demonstrated that genetic factors play an important role 
in the pathogenesis of  vitiligo.23 Probably the earliest 
evidence on the genetic basis of  vitiligo was described by 
Addison in 1855 in the patients with Addison’s disease, 
vitiligo, and pernicious anemia.24 Familial aggregation 
of  vitiligo was noted as early as 193325 and a positive 
family history was obtained in 56.8% of  families studied, 
57.1% of  them having two or more affected relatives.26 
Moreover, Alkhateeb et al found that the concordance for 
vitiligo in monozygotic twins was 23%, supporting the 
roles for both genetic and non-genetic factors in disease 
pathogenesis.27 Furthermore, studies on the genetic bases 
of  vitiligo in the United States and India revealed genetic 
model of  autosomal recessive for vitiligo with 3 or 4 loci 
controlling the disease.28,29
To date, approximately 33 vitiligo susceptibility loci 
have been identified. Almost 90% of  them encode 
immunoregulatory proteins and about 10% encode 
melanocyte proteins.30 The candidate genes include 
ACE, AIRE, CAT, CD4, CLEC11A, COMT, CTLA4, 
C12orf10, DDR1, EDN1, ESR1, FAS, FBXO11, FOXD3, 
FOXP3, GSTM1, GSTT1, IL1RN, IL10, KITLG, MBL2, 
NFE2L2, PDGFRA-KIT, PTGS2, STAT4, TAP1-
PSMB8, TGFBR2, TNF, TSLP, TXNDC5, UVRAG, 
VDR, and XBP1. Only 3 genes of  FOXP3, XBP1 and 
TSLP showed an association with the disease.31
FOXP3 gene (Xp11.23 region) encodes protein – 
scurfine (SFN). Dysregulation of  regulatory T cells 
(Tregs), specifically CD4+CD25+ and Forkhead box P3+ 
(FoxP3+) Tregs may be one of  the factors that can break 
tolerance to melanocyte self-antigens and contribute to 
vitiligo pathogenesis.32-35 Birlea et al in a meta-analysis 
screening 37 SNPs of  FOXP3 gene found the greatest 
significance with a promoter SNP rs3761547 and valid 
linkage disequilibrium with rs11798415 and rs5906843 
block.36 Song et al also screened 3 promoter SNPs of 
FOXP3 gene (rs3761548, rs2232365, and rs5902434) in 
Han Chinese populations (in 682 vitiligo patients and 682 
vitiligo -free age- and sex-matched controls) and found 
significant association of  rs3761548 and rs2232365 with 
vitiligo risk.37 At the same time, Jahan et al determined 
FOXP3 gene rs3761548 in the genomic DNA isolated 
from blood samples of  303 Indian patients and 305 
controls.38 Moreover, Elela et al found lower levels of 
FoxP3 in skin biopsies from 84 non-segmental vitiligo 
patients and 80 controls.39 In order to study the role of 
Tregs in vitiligo pathogenesis, Hegab and Attia evaluated 
FoxP3+ peripheral Tregs (CD4+CD25+) in 80 Egyptian 
patients and 60 healthy controls. Results revealed low 
numbers of  both peripheral CD4+CD25+ and FoxP3+ 
T cells in the vitiligo patients compared to the control 
subjects.40
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The next gene, XBP1 (X-box binding protein 1) is 
localized on chromosome 22 and plays the role of  a 
transcription factor through recognition of  the X2 
promoter element of  both HLA DR-α and HLA DP-
β.41,42 In 2009, Ren et al surveyed sequences of  XBP1 
in 319 cases and 294 controls of  Han Chinese and 
showed an elevated expression of  XBP1 in the lesional 
skins of  patients carrying the risk-associated C allele of 
rs2269577.43 Tarlé et al also studied 596 affected children 
and both parents in Southern Brazilian population and 
found a positive association between marker rs2239815 
and vitiligo and the relation of  rs2269577 with 2 SNPs in 
strong linkage disequilibrium.44 In order to investigate the 
association between oxidative stress (as a vitiligo trigger) 
and disease progression, Toosi et al demonstrated that 
phenols indeed up-regulated the expression of  unfolded 
protein response in melanocytes, including XBP1 in 
melanocytes.45
The third gene, TSLP (thymic stromal lymphopoietin, 
5q22.1) induces naive CD4+ T cells to produce Th2 
cytokines. The blockade of  TSLP or TSLP receptor 
induces low production of  Th2 cytokines and strong 
Th1 response that play an important role in vitiligo 
development.46 In 2009, Cheong et al examined the 
relation between 4 SNPs of  TSLP gene and vitiligo in 
160 Korean vitiligo patients and 568 healthy individuals 
and showed C allele at the TSLP -847C>T polymorphism 
may increase susceptibility to vitiligo through decreasing 
TSLP expression.47 Moreover, many studies determined 
the localization of  alleles and antigens predisposing 
vitiligo within the HLA. For instance, in the study 
of  Jin et al, clinical features of  vitiligo patients with 
HLA-DRB1*07 positive and negative were compared 
among the Han Chinese population. Patients with 
HLA-DRB1*07 positive showed an earlier disease 
onset, higher frequency in the family, and coexistence of 
autoimmune diseases compared with DRB1*07 negative 
patients. In Caucasians, in the MHC I region, the major 
association signal was in strong linkage disequilibrium 
with HLA-A*02. In the MHC II region, the major 
association signal was located between HLA-DRB1 and 
HLA-DQA1, in moderate linkage disequilibrium with 
HLA-DRB1*04.48
Conclusion
Altogether, the common studies revealed the highest 
prevalence rate of  vitiligo in African countries, but with 
regard to the distribution of  disease in different areas, 
environmental factors are as other causes of  vitiligo. In 
addition, some polymorphisms of  three genes of  FOXP3, 
XBP1 and TSLP showed the most relation with vitiligo 
and thus can be potential therapeutic targets. Therefore, 
more genetic studies are needed to discover genes and 
causes linked to clinical aspects of  the disease. It is 
hoped that investigation of  biological pathways involved 
in vitiligo pathogenesis will introduce new methods for 
the treatment, diagnosis, and prevention of  the disease in 
individuals with inherited susceptibility.
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